Form 4: Apellis Pharmaceuticals Director Exercises Stock Options and Reports Beneficial Ownership
SEC Form 4
Director A. Sinclair Dunlop exercised stock options and reported changes in beneficial ownership of Apellis Pharmaceuticals stock.
Summary
- On September 23, 2024, A. Sinclair Dunlop, a director of Apellis Pharmaceuticals, exercised stock options to acquire 4,600 shares of common stock at a price of $13.19 per share.
- Following this transaction, Dunlop directly owns 152,126 shares of Apellis Pharmaceuticals common stock.
- Dunlop is also an indirect owner of 100,000 shares held by Epidarex.
- The exercised stock options were granted on January 1, 2019, and were fully vested.
Sentiment
Score: 5
Explanation: This is a neutral report on stock option exercise and ownership changes, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a director's confidence in the company, but the number of shares involved is relatively small.
Key Dates
| Date | Description |
|---|---|
| January 1, 2019 | Stock options were granted and fully vested. |
| September 23, 2024 | Director exercised stock options. |
| September 24, 2024 | Date of the report. |
| December 31, 2028 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.